|
Synonyms: JNJ-64007957 | teclistamab-cqyv | Tecvayli®
teclistamab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Teclistamab (JNJ-64007957) is a bispecific IgG4 monoclonal antibody that simultaneously engages CD3 on the surface of T cells, and B-cell maturation antigen (BCMA) that is expressed on the surface of multiple myeloma (MM) cells, to induce a T cell-mediated cytotoxic immune response against the BCMA +ve cells [2].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. EMA (2022) | FDA (2022) | China NMPA (2024) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10928 | teclistamab |
| Synonyms |
| JNJ-64007957 | teclistamab-cqyv | Tecvayli® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 894 |
| Other databases | |
| GtoPdb PubChem SID | 473153821 |
| Search PubMed clinical trials | teclistamab |
| Search PubMed titles | teclistamab |
| Search PubMed titles/abstracts | teclistamab |
